FindTrial
Sign In

Analysis of Esophageal cancer patients who have received chemotherapy before Surgery

Retrospective analysis of patients with locally advanced esophageal cancer with involvement of the tracheobronchial tree who have received neoadjuvant chemotherapy

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2017/05/008491
Enrollment
100
Registered
2017-05-05
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Esophageal Cancer Patients

Interventions

Intervention1: Not Applicable: Not Applicable Control Intervention1: Not Applicable: Not Applicable

Sponsors

Nil
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: We will include all patients who have esophageal cancer and evidence of airway involvement, who are planned for induction chemotherapy, followed by reassessment. Airway involvement is defined as at least one of the following criteria: 1. Bronchoscopic appearance of external compression or bulge into the tracheal or bronchial lumen, in a patient in whom upfront chemoradiotherapy or radiotherapy was not offered, and who was planned for induction chemotherapy 2. Bronchoscopic appearance of restricted mobility or immobility of the mucosa of the trachea or bronchi, in a patient in whom upfront chemoradiotherapy or radiotherapy was not offered, and who was planned for induction chemotherapy 3. Bronchoscopic appearance of endotracheal or endobronchial tumor. 4. Clinical diagnosis of stridor, when other causes of stridor have been ruled out and the cause of stridor is clinically due to airway obstruction. We will include patients who have started chemotherapy from Nov 2010 onwards to 15 Jan 2015.

Exclusion criteria

Exclusion criteria: Patients who are planned for palliative intent therapy or best supportive care.

Design outcomes

Primary

MeasureTime frame
To assess the impact of induction chemotherapy in patients with esophageal cancer and airway involvement, in terms of the ability to deliver curative intent therapy. Timepoint: 10-12 weeks—

Secondary

MeasureTime frame
1. Overall survival 2. Progression-free survival 3. Response rate 4. Evaluate factors that affect toxicity. 5. Evaluate factors that affect survival. 6. Rate of development of TEF during induction chemotherapy. 7. Rate of development of TEF during definitive intent therapy. Timepoint: 10- 12 weeks—

Countries

India

Contacts

Public ContactDr Vanita Noronha

tata memorial hospital

vanita.noronha@gmail.com09769331525

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026